[144] Arteris, Inc. SEC Filing

Rhea-AI Filing Summary

Arteris, Inc. (AIP) filed a Form 144 reporting a planned sale of 12,978 common shares valued at $114,725.52, representing part of ~42.65 million shares outstanding, with an approximate sale date of 09/05/2025 on NASDAQ. The shares were acquired as restricted stock units on 09/01/2025 and are scheduled for sale the same month. The filing also discloses sales by Laurent Moll totaling 84,380 shares for aggregate gross proceeds of $915,838.75 over the past three months, including transactions executed under a 10b5-1 plan. The filer certifies no undisclosed material adverse information.

Positive

• Planned sale is documented under Rule 144, showing regulatory compliance
• Acquisition method disclosed as Restricted Stock Units, clarifying origin of shares
• Recent sales include 10b5-1 plan transactions, indicating prearranged trading intent

Negative

• Insider sales total 84,380 shares in the past three months, which may attract investor attention
• Aggregate gross proceeds of $915,838.75 from recent insider sales represent realized insider dispositions

Insights

Financial Analyst

TL;DR: Insider selling of RSUs and recent 10b5-1 activity is disclosed; sale size is modest relative to shares outstanding.

The filing shows an insider intends to sell 12,978 RSU-derived shares valued at $114,725.52 on or about 09/05/2025, with the securities acquired 09/01/2025. Recent insider dispositions total 84,380 shares for $915,838.75 over three months, several via a 10b5-1 plan. From an analytical perspective, the absolute dollar amounts and share counts are modest versus the reported ~42.65 million shares outstanding, suggesting limited immediate dilutive or market-impact risk. The presence of a 10b5-1 plan indicates prearranged trading intent, reducing signaling uncertainty.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 and notes 10b5-1 plan usage; signatures certify absence of undisclosed material information.

The Form 144 discloses the nature of acquisition (restricted stock units) and that certain prior sales were executed under a 10b5-1 plan, which is consistent with structured insider trading compliance. The filer explicitly represents no undisclosed material adverse information. For governance review, documentation of plan adoption dates and adherence to blackout periods would be relevant but are not detailed beyond the table entries.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	12978	114725.52	42649917	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Restricted Stock Units	Issuer			12978	09/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	09/02/2025	42692	381739.06
10b5-1 Sales Plan for LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	08/05/2025	34400	466763.28
10b5-1 Sales Plan for LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/29/2025	736	8022.40
10b5-1 Sales Plan for LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/03/2025	1554	14342.21
LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/02/2025	4704	42300.25
10b5-1 Sales Plan for LAURENT MOLL 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/01/2025	294	2671.55

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arteris (AIP) report in this Form 144 filing?

The filing reports a proposed sale of 12,978 common shares valued at $114,725.52, with an approximate sale date of 09/05/2025 on NASDAQ.

How were the shares to be sold acquired?

The shares were acquired as Restricted Stock Units on 09/01/2025 and the filing shows payment/vesting dated 09/01/2025.

How many shares did insiders sell in the past three months?

Insiders (Laurent Moll and related 10b5-1 plans) sold a total of 84,380 shares for $915,838.75 in the past three months.

Were any of the recent sales executed under a trading plan?

Yes; several transactions are identified as executed under a 10b5-1 Sales Plan for Laurent Moll.

What representation does the filer make about material information?

By signing, the filer represents they do not know any material adverse information